Enanta Pharmaceuticals Inc (ENTA)
13.31
+0.08
(+0.60%)
USD |
NASDAQ |
Apr 19, 16:00
13.31
0.00 (0.00%)
After-Hours: 20:00
Enanta Pharmaceuticals Enterprise Value: -55.56M for April 19, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| April 19, 2024 | -55.56M |
| April 18, 2024 | -57.26M |
| April 17, 2024 | -40.97M |
| April 16, 2024 | -12.19M |
| April 15, 2024 | 4.518M |
| April 12, 2024 | 10.87M |
| April 11, 2024 | 17.21M |
| April 10, 2024 | 12.77M |
| April 09, 2024 | 18.69M |
| April 08, 2024 | 8.961M |
| April 05, 2024 | 12.13M |
| April 04, 2024 | 5.153M |
| April 03, 2024 | 16.37M |
| April 02, 2024 | 8.750M |
| April 01, 2024 | 22.92M |
| March 28, 2024 | 32.23M |
| March 27, 2024 | 12.56M |
| March 26, 2024 | 0.2872M |
| March 25, 2024 | -42.24M |
| March 22, 2024 | -28.48M |
| March 21, 2024 | -27.64M |
| March 20, 2024 | -30.39M |
| March 19, 2024 | -40.12M |
| March 18, 2024 | -51.33M |
| March 15, 2024 | -36.52M |
| Date | Value |
|---|---|
| March 14, 2024 | -43.93M |
| March 13, 2024 | -31.66M |
| March 12, 2024 | -29.54M |
| March 11, 2024 | -18.12M |
| March 08, 2024 | -11.35M |
| March 07, 2024 | -4.579M |
| March 06, 2024 | -5.848M |
| March 05, 2024 | -18.54M |
| March 04, 2024 | -6.060M |
| March 01, 2024 | -12.41M |
| February 29, 2024 | -33.14M |
| February 28, 2024 | -34.62M |
| February 27, 2024 | -39.91M |
| February 26, 2024 | -40.12M |
| February 23, 2024 | -52.39M |
| February 22, 2024 | -72.49M |
| February 21, 2024 | -62.55M |
| February 20, 2024 | -66.57M |
| February 16, 2024 | -62.33M |
| February 15, 2024 | -56.62M |
| February 14, 2024 | -57.68M |
| February 13, 2024 | -76.72M |
| February 12, 2024 | -76.30M |
| February 09, 2024 | -76.09M |
| February 08, 2024 | -75.66M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-197.65M
Minimum
Nov 13 2023
1.735B
Maximum
Nov 05 2021
666.74M
Average
668.57M
Median
Jun 10 2020
Enterprise Value Benchmarks
| Madrigal Pharmaceuticals Inc | 3.700B |
| Galectin Therapeutics Inc | 256.92M |
| Viking Therapeutics Inc | 6.006B |
| Akero Therapeutics Inc | 904.93M |
| 89bio Inc | 311.52M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -33.41M |
| Revenue (Quarterly) | 18.00M |
| Total Expenses (Quarterly) | 52.89M |
| EPS Diluted (Quarterly) | -1.58 |
| Profit Margin (Quarterly) | -185.6% |
| Earnings Yield | -49.29% |
| Normalized Earnings Yield | -49.29 |